ADMA BIOLOGICS, INC. quarterly report, Q2 FY2016

ADMA Biologics, Inc. — Form 10-Q Summary

Reporting period: Three and six months ended June 30, 2016; filed August 12, 2016. The interim financial statements are unaudited and prepared under U.S. GAAP.

Business context

ADMA is a late-stage biopharmaceutical company developing plasma-based biologics, led by RI-002 for primary immune deficiency disease (PIDD). Its two FDA-licensed Georgia plasma collection centers generate plasma sales and supply a portion of ADMA’s manufacturing needs. The company has not yet generated revenue from its therapeutic product development business.

Key financial metrics

MetricQ2 2016Q2 2015Six months 2016Six months 2015
Total revenue$2.27 million$1.31 million$4.40 million$2.81 million
Product revenue$2.24 million$1.29 million$4.32 million$2.78 million
Gross profit$0.93 million$0.52 million$1.78 million$1.12 million
Gross margin40.8%40.0%40.6%39.7%
Loss from operations$(5.49) million$(3.52) million$(9.65) million$(6.72) million
Net loss$(6.01) million$(4.68) million$(10.62) million$(8.28) million
Net loss per share$(0.50)$(0.44)$(0.93)$(0.81)
Operating cash flowNot separately providedNot separately provided$(9.97) million$(8.67) million

Research and development expense increased to $3.40 million in the quarter and $5.43 million for the six months, primarily due to RI-002 validation, testing, production and regulatory consulting. Total operating expenses rose 61% year over year in the quarter and 47% for the six-month period.

Liquidity, debt and capital resources

  • At June 30, 2016, cash and cash equivalents were $12.55 million and short-term investments were $11.27 million.
  • Working capital was approximately $24.4 million; total assets were $31.74 million and total liabilities were $27.83 million.
  • Oxford debt had gross principal of $20.0 million and a carrying value of $18.05 million, net of debt discounts. An additional $5.0 million may be available if RI-002 receives FDA approval by January 31, 2017.
  • Debt bears interest at the greater of 7.80% or three-month LIBOR plus 7.54%; principal repayment was scheduled to begin in February 2017 unless the additional tranche is drawn.
  • The May 2016 equity offering issued 2.18 million shares and generated approximately $13.0 million of net proceeds. Common shares outstanding increased to 12.89 million from 10.71 million at December 31, 2015.
  • Management believed existing cash, investments and accounts receivable would fund operations, as currently conducted, into the second half of 2017. This estimate was dependent on regulatory timing, manufacturing scale-up and spending levels.

Material changes versus the prior comparable period

  • Six-month revenue increased 56%, principally because the Marietta, Georgia plasma center received FDA approval during the third quarter of 2015 and contributed additional plasma sales.
  • Six-month net loss increased 28%, reflecting substantially higher RI-002 development spending, plasma-center expenses and general and administrative costs.
  • Operating cash use increased to $9.97 million from $8.67 million, while financing cash inflows increased to $17.04 million from $10.59 million.
  • Interest expense increased because of the additional $4.0 million Oxford borrowing, although the prior-period $0.7 million debt-extinguishment loss did not recur.
  • Inventories rose to $4.21 million from $3.45 million, primarily reflecting normal-source and RSV high-titer plasma accumulation and purchases.

Outlook, commentary, risks and unusual items

  • After quarter-end, in July 2016, the FDA issued a Complete Response Letter for the RI-002 BLA. The FDA did not identify concerns with the submitted clinical safety or efficacy data and did not request additional clinical studies, but cited inspection deficiencies involving third-party manufacturing, fill-and-finish and testing vendors. Approval is contingent on resolving these issues and providing requested documentation.
  • The CRL delayed the anticipated RI-002 commercial launch. The FDA had not finalized product labeling, and the company could face additional regulatory requests even after deficiencies are addressed.
  • Management expected research and development and general and administrative expenses to continue increasing during 2016 because of regulatory activities, validation, manufacturing, market research, commercial planning and hiring.
  • The company has incurred cumulative losses of approximately $98.0 million since inception and expects continued losses and negative operating cash flow. Additional equity or debt financing may be required and could dilute shareholders or impose additional restrictions.
  • Revenue is substantially attributable to one customer, increasing customer-concentration risk. The company also depends on third-party manufacturers, vendors and plasma availability.
  • Minimum rent under the Georgia facility leases totaled approximately $2.8 million through the lease expirations. Management reported no legal claims expected to have a material adverse effect.
  • On August 12, 2016, ADMA entered into an amended services agreement with Areth LLC, a company controlled by Vice Chairman Jerrold Grossman, for warehousing, distribution, office and administrative services at $16,000 per month.

Investor verification points

  • Confirm the status and timing of remediation of the third-party vendor deficiencies identified in the July 2016 CRL and any subsequent FDA correspondence.
  • Assess whether the company’s projected liquidity into the second half of 2017 remains realistic after regulatory delays and increased commercialization costs.
  • Review Oxford loan covenants, repayment dates, interest costs, final payment obligations and the conditions for accessing the additional $5.0 million.
  • Monitor cash burn, inventory levels and customer concentration in plasma revenue.
  • Evaluate potential dilution from future equity financing, outstanding options and warrants, and the effect of any additional debt.